Información del artículo
Abstract
The following article is a narrative review on isolated nocturnal hypertension, conducted up to July 2024, with a search for primary and secondary articles in MEDLINE, LILACS, and gray literature.
This review highlights aspects related to its current definition, epidemiology, and associated populations and risk factors, as well as specifics regarding its diagnosis, prognostic importance for target organ damage and cardiovascular events/mortality, and potential treatments.
This condition has particular aspects and, although it is not very common in the general population, it reaches high prevalence in some at-risk populations. To date, there is much debate and many issues to investigate regarding diagnostic aspects, as well as its heterogeneity and clinical significance, which indicate different prognoses. Therapeutic aspects are even more a matter of debate, necessitating future research.
Keywords:
Hypertension
Blood pressure monitoring ambulatory
Circadian rhythm
Blood pressure
Masked hypertension
Prehypertension
Abbreviations:
ABPM
HBPM
LVH
CAP
PWV
CKD
HIV
BMI
SBP
TOD
Resumen
El siguiente artículo es una revisión narrativa sobre la hipertensión nocturna aislada, realizada hasta julio de 2024, con una búsqueda de artículos primarios y secundarios en MEDLINE, LILACS y literatura gris.
Esta revisión destaca aspectos relacionados con su definición actual, epidemiología, poblaciones asociadas y factores de riesgo, así como detalles específicos sobre su diagnóstico, importancia pronóstica en el daño de órganos blanco y eventos/mortalidad cardiovascular, y posibles tratamientos.
Esta condición presenta particularidades y, aunque no es muy común en la población general, alcanza una alta prevalencia en algunas poblaciones de riesgo. Hasta la fecha, existe un amplio debate y muchas cuestiones por investigar en relación con los aspectos diagnósticos, su heterogeneidad y significado clínico, lo que indica diferentes pronósticos. Los aspectos terapéuticos son aún más debatidos, lo que resalta la necesidad de futuras investigaciones.
Palabras clave:
Hipertensión
Monitoreo ambulatorio de presión arterial
Ritmo circadiano
Presión arterial
Hipertensión enmascarada
Prehipertensión
Artículo
Opciones para acceder a los textos completos de la publicación Hipertensión y Riesgo Vascular
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
References
[1]
R.(Chair) Sánchez, A.(Co-Chair) Coca, D.I. Molina de Salazar, L. Alcocer, D. Aristizabal, E. Barbosa, et al.
LASH Guidelines Task Force Steering and Writing Committee. 2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America.
J Hypertens, 43 (2025), pp. 1-34
[2]
P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey Jr., K.J. Collins, C. Dennison Himmelfarb, et al.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Hypertension, 71 (2018), pp. 1269-1324
[3]
B. Williams, G. Mancia, W. Spiering, E. Agabiti Rosei, M. Azizi, M. Burnier, et al.
Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.
J Hypertens, 36 (2018), pp. 1953-2041
[4]
G. Mancia, R. Kreutz, M. Brunström, M. Burnier, G. Grassi, A. Januszewicz, et al.
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).
J Hypertens, 41 (2023), pp. 1874-2071
[5]
T. Unger, C. Borghi, F. Charchar, N.A. Khan, N.R. Poulter, D. Prabhakaran, et al.
2020 international society of hypertension global hypertension practice guidelines.
Hypertension, 75 (2020), pp. 1334-1357
[6]
Y. Li, J.A. Staessen, L. Lu, L.H. Li, G.L. Wang, J.G. Wang.
Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study.
Hypertension, 50 (2007), pp. 333-339
[7]
K. Kario, H. Kanegae, N. Tomitani, Y. Okawara, T. Fujiwara, Y. Yano, et al.
Nighttime blood pressure measured by home blood pressure monitoring as an independent predictor of cardiovascular events in general practice.
Hypertension, 73 (2019), pp. 1240-1248
[8]
H.Q. Fan, Y. Li, L. Thijs, T.W. Hansen, J. Boggia, M. Kikuya, et al.
International database on ambulatory blood pressure in relation to cardiovascular outcomes investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations.
J Hypertens, 28 (2010), pp. 2036-2045
[9]
G. Ogedegbe, T.M. Spruill, D.F. Sarpong, C. Agyemang, W. Chaplin, A. Pastva, et al.
Correlates of isolated nocturnal hypertension and target organ damage in a population-based cohort of African Americans: the Jackson Heart Study.
Am J Hypertens, 26 (2013), pp. 1011-1016
[10]
C. Cuspidi, R. Facchetti, M. Bombelli, C. Sala, M. Tadic, G. Grassi, et al.
Is night-time hypertension worse than daytime hypertension? A study on cardiac damage in a general population: the PAMELA study.
J Hypertens, 35 (2017), pp. 506-512
[11]
M.R. Salazar, W.G. Espeche, E. Balbín, C.E. Leiva Sisnieguez, J. Minetto, B.C. Leiva Sisnieguez, et al.
Prevalence of isolated nocturnal hypertension according to 2018 European Society of Cardiology and European Society of Hypertension office blood pressure categories.
J Hypertens, 38 (2020), pp. 434-440
[12]
J.R. Banegas, L.M. Ruilope, A. de la Sierra, J.J. de la Cruz, M. Gorostidi, J. Segura, et al.
High prevalence of masked uncontrolled hypertension in people with treated hypertension.
Eur Heart J, 35 (2014), pp. 3304-3312
[13]
J. Barochiner, R.R. Díaz, R. Martínez.
Prevalence and characteristics of isolated nocturnal hypertension and masked nocturnal hypertension in a tertiary hospital in the city of Buenos Aires.
Diagnostics (Basel), 13 (2023), pp. 1419
[14]
M.Y. Rhee, J.S. Kim, C.H. Kim, J.H. Kim, J.H. Lee, S.W. Kim, et al.
Prevalence and characteristics of isolated nocturnal hypertension in the general population.
Korean J Intern Med, 36 (2021), pp. 1126-1133
[15]
Gorostidi M, De la Sierra A, Segura J, Tranche S, Lopez-Zuniga MC, García-Puig J, et al., on behalf of the Spanish Society of Hypertension ABMP Registry. Prevalence of isolated nocturnal hypertension in treated hypertensives. The Spanish Society of Hypertension ABPM Registry. J Hypertens 2008;26(Suppl 1):S502-3.
[16]
C. Cuspidi, F. Paoletti, M. Tadic, C. Sala, E. Gherbesi, R. Dell’Oro, et al.
Nocturnal blood pressure: the dark side of white-coat hypertension.
J Hypertens, 38 (2020), pp. 2404-2408
[17]
C. Cuspidi, M. Rescaldani, M. Tadic, C. Sala, G. Grassi, G. Mancia.
Whitecoat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis.
J Hypertens, 33 (2015), pp. 24-32
[18]
R. Sega, G. Trocino, A. Lanzarotti, S. Carugo, G. Cesana, R. Schiavina, et al.
Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study).
Circulation, 104 (2001), pp. 1385-1392
[19]
J.B. Cohen, M.J. Lotito, U.K. Trivedi, M.G. Denker, D.L. Cohen, R.R. Townsend.
Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis.
Ann Intern Med, 170 (2019), pp. 853-862
[20]
C. Wang, W.J. Deng, W.Y. Gong, J. Zhang, H. Tang, H. Peng, et al.
High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease.
J Am Heart Assoc, 4 (2015), pp. e002025
[21]
X. Li, J. Ke, X. Chen, M. Yin, T. Lou, J. Zhang, et al.
Different effects of morning and nocturnal hypertension on target organ damage in chronic kidney disease.
J Clin Hypertens (Greenwich), 23 (2021), pp. 1051-1059
[22]
G. Vareta, P.I. Georgianos, V. Vaios, V. Sgouropoulou, S. Roumeliotis, A. Georgoulidou, et al.
Epidemiology of hypertension among patients on peritoneal dialysis using standardized office and ambulatory blood pressure recordings.
Am J Nephrol, 53 (2022), pp. 139-147
[23]
M. Wijkman, T. Länne, J. Engvall, T. Lindström, C.J. Ostgren, F.H. Nystrom.
Masked nocturnal hypertension – a novel marker of risk in type 2 diabetes.
Diabetologia, 52 (2009), pp. 1258-1264
[24]
H. Fujita, S. Matsuoka, M. Awazu.
Masked isolated nocturnal hypertension in children and young adults.
Pediatr Cardiol, 39 (2018), pp. 66-70
[25]
P. Călin, M. Viorel, P. Luchiana, C. Mihaela, P. Lavinia.
Masked nocturnal hypertension as a result of high prevalence of non-dippers among apparently well-controlled hypertensive patients with type 2 diabetes mellitus: data from a prospective study.
Diabetol Metab Syndr, 14 (2022), pp. 130
[26]
T.A. Bhat, M.R. Mir, S. Naqati, M. Naik, M. Naqash.
Hypertensive phenotypes and pattern of ambulatory blood pressure in patients of diabetes mellitus of Kashmir Valley.
Indian J Endocrinol Metab, 26 (2022), pp. 55-60
[27]
C.-R.S. Naun, C. Evelyn, M. Rosa, O. Allan.
Monitoreo ambulatorio de la presión arterial en pacientes diabéticos con o sin hipertensión arterial.
Med Interna Méx [revista en la Internet], 34 (2018), pp. 855-863
[28]
A. Düzova, A. Karabay Bayazit, N. Canpolat, A. Niemirska, I. Kaplan Bulut, K. Azukaitis, et al.
Isolated nocturnal and isolated daytime hypertension associate with altered cardiovascular morphology and function in children with chronic kidney disease: findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease study.
J Hypertens, 37 (2019), pp. 2247-2255
[29]
A. Iturzaeta, L. Pompozzi, C. Casas Rey, I. Passarelli, F. Torres.
Prevalencia de hipertensión enmascarada en niños con factores de riesgo para el desarrollo de hipertensión arterial.
Arch Argent Pediatr, 116 (2018), pp. 328-332
[30]
J. Sołtysiak, B. Skowrońska, K. Maćkowiak-Lewandowicz, A. Blumczyński, K. Elżbieta, D. Ostalska-Nowicka, et al.
Ambulatory blood pressure parameters and their association with albuminuria in adolescents with type 1 diabetes mellitus.
Pediatr Nephrol, (2024),
[31]
D. Baltu, B.V. Salancı, B. Gülhan, F. Özaltın, A. Düzova, R. Topaloğlu.
Albuminuria is associated with 24-h and night-time diastolic blood pressure in urinary tract infection with renal scarring.
Turk J Pediatr, 65 (2023), pp. 620-629
[32]
T. Seeman, M. Pfaff, C.B. Sethna.
Isolated nocturnal hypertension in pediatric kidney transplant recipients.
Pediatr Transplant, 26 (2022), pp. e14192
[33]
M. Awazu.
Isolated nocturnal hypertension in children.
Front Pediatr, 10 (2022), pp. 823414
[34]
T. Hill-Horowitz, K. Merchant, M. Abdullah, L. Castellanos-Reyes, P. Singer, H. Dukkipati, et al.
Reclassification of adolescent ambulatory prehypertension and unclassified blood pressures by 2022 American Heart Association Pediatric Ambulatory Blood Pressure Monitoring Guidelines.
J Pediatr, 266 (2024), pp. 113895
[35]
S. Andrea, C. Jaime, G. Claudia.
Monitorización ambulatoria de presión arterial en escolares con antecedente de prematurez extrema.
Rev Chil Pediatr, 89 (2018), pp. 18-23
[36]
N. Bansal, W.A. Raedi, S.S. Medar, L. Abraham, K. Beddows, D.T. Hsu, et al.
Masked hypertension in pediatric heart transplant recipients.
Pediatr Cardiol, 44 (2023), pp. 1003-1008
[37]
M. Koudelka, E. Sovová.
The key role of ambulatory blood pressure monitoring in the detection of masked hypertension and other phenomena in frail geriatric patients.
Medicina (Kaunas), 57 (2021), pp. 1221
[38]
H. Guo, Y. Tabara, M. Igase, M. Yamamoto, N. Ochi, T. Kido, et al.
Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J-SHIPP study.
Hypertens Res, 33 (2010), pp. 32-36
[39]
I.B. Goldstein, G. Bartzokis, D. Guthrie, D. Shapiro.
Ambulatory blood pressure and brain atrophy in the healthy elderly.
Neurology, 59 (2002), pp. 713-719
[40]
A. Gómez-Berrocal, I. De Los Santos-Gil, D. Abad-Pérez, Á. Gutiérrez-Liarte, P. Ibáñez-Sanz, J. Sanz-Sanz, et al.
Ambulatory blood pressure monitoring in HIV-infected patients: usefulness for cardiovascular risk assessment.
J Int Assoc Provid AIDS Care, 19 (2020),
[41]
W. Espeche, M.R. Salazar, J. Minetto, C. Suarez-Fernandez, I. De Los Santos Gil, A. Gomez Berrocal.
Hipertensión nocturna aislada en individuos con el virus de la inmunodeficiencia humana.
Hipertens Riesgo Vasc, 39 (2022), pp. 149-156
[42]
M.G. Zanuzzi, S.M. López, M.J. Cattaneo, M.A. Pérez-Maure, C.D. Lahiri, C.A. Romero.
Isolated nocturnal hypertension in people living with human immunodeficiency virus: a cross-sectional study.
Am J Hypertens, 37 (2024), pp. 127-133
[43]
W. Kositanurit, T. Suksiriworaboot, G. Nakornchai, A. Avihingsanon, P. Chattranukulchai.
High prevalences of nocturnal hypertension and isolated nocturnal hypertension in long-standing virally suppressed people living with human immunodeficiency virus.
J Hypertens, 42 (2024), pp. e194-e195
[44]
K.A. Armah, C.C. Chang, J.V. Baker, V.S. Ramachandran, BudoffMJ, H.M. Crane, et al.
Veterans Aging Cohort Study (VACS) Project Team Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and-uninfected veterans.
Clin Infect Dis, 58 (2014), pp. 121-129
[45]
S.A. Fahme, G.S. Bloomfield, R. Peck.
Hypertension in HIV-infected adults: novel pathophysiologic mechanisms.
Hypertension, 72 (2018), pp. 44-55
[46]
R.B. D’Agostino Sr..
Cardiovascular risk estimation in2012: lessons learned and applicability to the HIV population.
J Infect Dis, 205 (2012), pp. S362-S367
[47]
G. Bilo, L. Acone, C. Anza-Ramírez, J.L. Macarlupú, D. Soranna, A. Zambon, et al.
Office and ambulatory arterial hypertension in highlanders: HIGHCARE-ANDES highlanders study.
Hypertension, 76 (2020), pp. 1962-1970
[48]
M. Tadic, C. Cuspidi, G. Grassi, G. Mancia.
Isolated nocturnal hypertension: what do we know and what can we do?.
Integr Blood Press Control, 13 (2020), pp. 63-69
[49]
K. Kario.
Nocturnal hypertension: new technology and evidence.
Hypertension, 71 (2018), pp. 997-1009
[50]
J. Minetto, M.B. Cuello, F.P. Dominici, C. Caniffi, A.M. Brizzio, G. Cerri, et al.
Circulating angiotensin-(1–7) is decreased in patients with isolated nocturnal hypertension.
J Hypertens, 42 (2024), pp. 1101-1104
[51]
R. Agarwal, R.P. Light, J.E. Bills, L.A. Hummel.
Nocturia, nocturnal activity, and nondipping.
Hypertension, 54 (2009), pp. 646-651
[52]
K. Kario.
Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure.
Hypertens Res, 32 (2009), pp. 428-432
[53]
Q.Y. He, J. Feng, X.L. Zhang, Z.A. Liang, S.G. Huang, J. Kang, et al.
Elevated nocturnal and morning blood pressure in patients with obstructive sleep apnea syndrome.
Chin Med J (Engl), 125 (2012), pp. 1740-1746
[54]
M. Hobzova, K. Sonka, M. Pretl, J. Vaclavik, E. Kriegova, M. Radvansky, et al.
Sleep apnoea in patients with nocturnal hypertension – a multicenter study in the Czech Republic.
Physiol Res, 67 (2018), pp. 217-231
[55]
Y. Tabara, T. Matsumoto, K. Murase, K. Setoh, T. Kawaguchi, T. Nakayama, et al.
Sleep-related factors associated with masked hypertension: the Nagahama study.
J Hypertens, 41 (2023), pp. 1298-1305
[56]
L. Varghese, G. Rebekah, N.P.A. Oliver, R. Kurien.
Oxygen desaturation index as alternative parameter in screening patients with severe obstructive sleep apnea.
Sleep Sci, 15 (2022), pp. 224-228
[57]
M.R. Salazar, W.G. Espeche, R.N. Stavile, L. Disalvo, A. Tournier, B.C. Leiva Sisnieguez, et al.
Nocturnal but not diurnal hypertension is associated to insulin resistance markers in subjects with normal or mildly elevated office blood pressure.
Am J Hypertens, 30 (2017), pp. 1032-1038
[58]
B.B. Albert, M. de Bock, J.G. Derraik, C.M. Brennan, J.B. Biggs, P.L. Hofman, et al.
Non-dipping and cardiometabolic profile: a study on normotensive overweight middle-aged men.
Heart Lung Circ, 25 (2016), pp. 1218-1225
[59]
C. Cuspidi, C. Sala, C. Valerio, F. Negri, G. Mancia.
Nocturnal blood pressure in untreated essential hypertensives.
Blood Press, 20 (2011), pp. 335-341
[60]
A. Kollias, K.G. Kyriakoulis, E. Stambolliu, A. Ntineri, I. Anagnostopoulos, G.S. Stergiou.
Seasonal blood pressure variation assessed by different measurement methods: systematic review and meta-analysis.
J Hypertens, 38 (2020), pp. 791-798
[61]
G.S. Stergiou, P. Palatini, P.A. Modesti, K. Asayama, R. Asmar, G. Bilo, et al.
Seasonal variation in blood pressure: evidence, consensus and recommendations for clinical practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability.
J Hypertens, 38 (2020), pp. 1235-1243
[62]
J.F. Huang, D.Y. Zhang, C.S. Sheng, D.W. An, M. Li, Y.B. Cheng, et al.
Isolated nocturnal hypertension in relation to host and environmental factors and clock genes.
J Clin Hypertens (Greenwich), 24 (2022), pp. 1255-1262
[63]
M. Shoghli, A.I. Lokki, M. Lääperi, J. Sinisalo, M.-L. Lokki, M. Hilvo, et al.
The novel ceramide- and phosphatidylcholine-based risk score for the prediction of new-onset of hypertension.
J Clin Med, 12 (2023), pp. 7524
[64]
A.S. Papazoglou, N. Stalikas, D.V. Moysidis, N. Otountzidis, A. Kartas, E. Karagiannidis, et al.
CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events: a systematic review and meta-analysis.
J Clin Lipidol, 16 (2022), pp. 272-276
[65]
D. Zhang, Q. Guo, Y. Cheng, J. Wang, Y. Li.
Circulating ceramide as a potential biomarker for isolated nocturnal hypertension.
J Hypertens, 39 (2021), pp. e106
[66]
G.S. Stergiou, P. Palatini, G. Parati, E. O’Brien, A. Januszewicz, E. Lurbe, European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability, et al.
2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement.
J Hypertens, 39 (2021), pp. 1293-1302
[67]
R.H. Fagard, H. Celis, L. Thijs, J.A. Staessen, D.L. Clement, M.L. De Buyzere, et al.
Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension.
Hypertension, 51 (2008), pp. 55-61
[68]
P. Verdecchia, F. Angeli, C. Borgioni, R. Gattobigio, G. Reboldi.
Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation.
Hypertension, 49 (2007), pp. 777-783
[69]
M. Abdalla, J. Goldsmith, P. Muntner, K.M. Diaz, K. Reynolds, J.E. Schwartz, et al.
Is isolated nocturnal hypertension a reproducible phenotype?.
Am J Hypertens, 29 (2016), pp. 33-38
[70]
M.-Y. Rhee.
Prevalence and characteristics of isolated nocturnal hypertension in treated patients.
J Hypertens, 42 (2024), pp. e193
[71]
H. Ushio, T. Ishigami, N. Araki, S. Minegishi, K. Tamura, Y. Okano, et al.
Utility and feasibility of a new programmable home blood pressure monitoring device for the assessment of night-time blood pressure.
Clin Exp Nephrol, 13 (2009), pp. 480-485
[72]
J. Ishikawa, S. Hoshide, K. Eguchi, S. Ishikawa, K. Shimada, K. Kario, et al.
Nighttime home blood pressure and the risk of hypertensive target organ damage.
Hypertension, 60 (2012), pp. 921-928
[73]
S. Davidson, C. Roman, L. Tarassenko.
Predicting isolated nocturnal hypertension using dawn and dusk home blood pressure monitoring.
Annu Int Conf IEEE Eng Med Biol Soc, 2022 (2022), pp. 3011-3014
[74]
A. de la Sierra, J. Redon, J.R. Banegas, J. Segura, G. Parati, M. Gorostidi, et al.
Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients.
Hypertension, 53 (2009), pp. 466-472
[75]
L. Thijs, T.W. Hansen, M. Kikuya, K. Björklund-Bodegård, Y. Li, E. Dolan, et al.
The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives.
Blood Press Monit, 12 (2007), pp. 255-262
[76]
J. Redon, E. Lurbe.
Nocturnal blood pressure versus nondipping pattern: what do they mean?.
Hypertension, 51 (2008), pp. 41-42
[77]
K. Kario, S. Hoshide, H. Haimoto, K. Yamagiwa, K. Uchiba, S. Nagasaka, et al.
Sleep blood pressure self-measured at home as a novel determinant of organ damage: Japan Morning Surge Home Blood Pressure (J-HOP) Study.
J Clin Hypertens (Greenwich), 17 (2015), pp. 340-348
[78]
L.H. Li, Y. Li, Q.F. Huang, C.S. Sheng, J.A. Staessen, J.G. Wang.
Isolated nocturnal hypertension and arterial stiffness in a Chinese population.
Blood Press Monit, 13 (2008), pp. 157-159
[79]
S. Hoshide, J. Ishikawa, K. Eguchi, T. Ojima, K. Shimada, K. Kario.
Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure.
Hypertens Res, 30 (2007), pp. 143-149
[80]
S.H. Kim, C. Shin, S. Kim, J.S. Kim, S.Y. Lim, H.S. Seo, et al.
Prevalence of isolated nocturnal hypertension and development of arterial stiffness, left ventricular hypertrophy, and silent cerebrovascular lesions: the KoGES (Korean Genome and Epidemiology Study).
J Am Heart Assoc, 11 (2022), pp. e025641
[81]
V. Presta, I. Figliuzzi, M. D’Agostino, B. Citoni, F. Miceli, F. Simonelli, et al.
Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension.
J Clin Hypertens (Greenwich), 20 (2018), pp. 1238-1246
[82]
C. Wang, Y. Li, J. Zhang, Z. Ye, Q. Zhang, X. Ma, et al.
Prognostic effect of isolated nocturnal hypertension in Chinese patients with nondialysis chronic kidney disease.
J Am Heart Assoc, 5 (2016),
[83]
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
N Engl J Med, 342 (2000), pp. 145-153
[84]
J.A. Staessen, R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhäger, et al.
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
Lancet, 350 (1997), pp. 757-764
[85]
R.C. Hermida, D.E. Ayala, A. Mojón, J.R. Fernández.
Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
Chronobiol Int, 27 (2010), pp. 1629-1651
[86]
R.C. Hermida, J.J. Crespo, M. Domínguez-Sardiña, A. Otero, A. Moyá, M.T. Ríos, et al.
Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.
Eur Heart J, 41 (2020), pp. 4565-4576
[87]
M. Brunström, S.E. Kjeldsen, R. Kreutz, K. Gjesdal, K. Narkiewicz, M. Burnier, et al.
Missing verification of source data in hypertension research: the HYGIA PROJECT in perspective.
Hypertension, 78 (2021), pp. 555-558
[88]
G. Guthrie, N. Poulter, T. Macdonald, I. Ford, I. Mackenzie, E. Findlay, et al.
Chronotherapy in hypertension: the devil is in the details.
Eur Heart J, 41 (2020), pp. 1606-1607
[89]
B. Lemmer, M. Middeke.
A commentary on the Spanish hypertension studies MAPEC and HYGIA.
Chronobiol Int, 37 (2020), pp. 728-730
[90]
R. Gupta, A.H. Malik, T. Popli, P. Ranchal, S. Yandrapalli, W.S. Aronow.
Impact of bedtime dosing of antihypertensives compared to morning therapy: a meta-analysis of randomised controlled trials.
Eur J Prev Cardiol, (2020),
[91]
M.D. Ruben, D.F. Smith, G.A. FitzGerald, J.B. Hogenesch.
Dosing time matters.
Science, 365 (2019), pp. 547-549
[92]
N.R. Poulter, C. Savopoulos, A. Anjum, M. Apostolopoulou, N. Chapman, M. Cross, et al.
Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-h ambulatory blood pressure.
Hypertension, 72 (2018), pp. 870-873
[93]
L.J. Laffin, G.L. Bakris.
Has the sun set on nighttime dosing in uncomplicated hypertension?.
Hypertension, 72 (2018), pp. 836-838
[94]
M. Rahman, T. Greene, R.A. Phillips, L.Y. Agodoa, G.L. Bakris, J. Charleston, et al.
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Hypertension, 61 (2013), pp. 82-88
[95]
P. Zhao, P. Xu, C. Wan, Z. Wang.
Evening versus morning dosing regimen drug therapy for hypertension.
Cochrane Database Syst Rev, 10 (2011), pp. CD004184
[96]
University of Alberta and collaborators. The Effect of Antihypertensive Medication Timing on Morbidity and Mortality NCT02990663. Available from: https://clinicaltrials.gov/study/NCT02990663.
[97]
A. Rogers, I. Morrison, D.A. Rorie, I.S. Mackenzie, T.M. MacDonald.
Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures.
BMJ Open, 8 (2018), pp. e021890
[98]
I.S. Mackenzie, A. Rogers, N.R. Poulter, B. Williams, M.J. Brown, D.J. Webb, et al.
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
Lancet, 400 (2022), pp. 1417-1425
